Posts
On December 31, the US Food and Drug
Administration approved Fulyzaq (Crofelemer) to treat diarrhea symptoms in
HIV/AIDS patients currently on antiretroviral therapy (ART).
Many ART patients either change or
discontinue their therapies because of the resultant diarrhea. Fulyzaq is
intended for HIV/AIDS patients whose diarrhea is not caused by infection from a
virus, bacteria, or parasite.
Derived from the red sap of the
Croton lechleri plant, Fulyzaq is only the second botanical prescription drug
approved by the FDA—a botanical drug can be a complex mixture derived from one
or more plant materials of varying degrees of purity.
Currently, there are no other
FDA-approved therapies for HIV-associated diarrhea, according to Julie Beitz,
MD, director of the Office of Drug Evaluation III in FDA’s Center for Drug
Evaluation and Research.
The Friends of AIDS Foundation is
dedicated to enhancing the quality of life for HIV positive individuals and
empowering people to make healthy choices to prevent the spread of the HIV
virus. To learn more about The Friends of AIDS Foundation, please visit: http://www.friendsofaids.org.
TOGETHER WE REMAIN STRONG!
